FY2024 EPS Estimate for PDS Biotechnology Lowered by Analyst

PDS Biotechnology Co. (NASDAQ:PDSB - Free Report) - Equities research analysts at B. Riley cut their FY2024 earnings per share (EPS) estimates for PDS Biotechnology in a note issued to investors on Monday, November 25th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($1.12) per share for the year, down from their previous estimate of ($1.06). B. Riley currently has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for PDS Biotechnology's current full-year earnings is ($1.18) per share. B. Riley also issued estimates for PDS Biotechnology's Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

Several other equities research analysts also recently commented on the stock. HC Wainwright restated a "buy" rating and issued a $21.00 price target on shares of PDS Biotechnology in a research report on Friday, November 15th. Alliance Global Partners raised shares of PDS Biotechnology to a "strong-buy" rating in a research note on Wednesday, August 21st. Finally, StockNews.com lowered PDS Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, November 9th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $11.67.

PDS Biotechnology Trading Up 1.9 %

Shares of PDS Biotechnology stock traded up $0.04 on Wednesday, reaching $2.15. 345,364 shares of the company were exchanged, compared to its average volume of 608,417. PDS Biotechnology has a fifty-two week low of $1.53 and a fifty-two week high of $6.68. The stock has a fifty day moving average price of $3.06 and a 200-day moving average price of $3.17. The firm has a market capitalization of $80.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.93. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC boosted its stake in PDS Biotechnology by 9.8% during the 3rd quarter. Geode Capital Management LLC now owns 415,113 shares of the company's stock valued at $1,586,000 after purchasing an additional 37,142 shares during the period. XTX Topco Ltd grew its stake in shares of PDS Biotechnology by 241.8% in the third quarter. XTX Topco Ltd now owns 67,182 shares of the company's stock worth $257,000 after acquiring an additional 47,528 shares during the last quarter. Vontobel Holding Ltd. increased its position in PDS Biotechnology by 233.3% during the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company's stock worth $153,000 after acquiring an additional 28,000 shares during the period. Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology during the 2nd quarter valued at $146,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in PDS Biotechnology in the 2nd quarter valued at $115,000. Institutional investors and hedge funds own 26.84% of the company's stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.